In a clinical trial involving intrathecal delivery of BDNF to ALS patients, doses of 150 mg/day were well tolerated; however, conclusions about treatment efficacy were unable to be drawn due to small sample sizes [185]. Here, BDNF is linked to amyotrophic lateral sclerosis.